Buy Ajanta Pharmaceuticals; target of Rs 1505: ICICI Direct

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

ICICI Direct's research report on Ajanta Pharmaceuticals

Ajanta Pharma is a focused player in branded, which constitutes ~72% of overall sales, spread across geographies including India. As of Q2FY23, overall exports: domestic formulations ratio was at 66:34 • Among exports, Asia accounts for ~41% of export formulations, Africa 29% and US 30%. The company also participates in anti-malarial tenders in Africa (included in Africa).

Outlook

We maintain BUY as it remains a compelling play on branded generics (~72% exposure) with strong execution track record and financials. Valued at Rs 1505 i.e. 22x P/E on FY24E EPS of Rs 68.3.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Ajanta Pharmaceuticals - 05-11-2022 - icici